CARA

Oral Korsuva

Atopic Dermatitis

Phase 2 (Top-line results)

Exp Date

H2 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Oral Korsuva for Atopic Dermatitis - Topline Data

  • ClinicalTrial.gov (NCT04018027): Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)


WHAT IS THE CATALYST EVENT?


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA


PRESS RELEASE

POSTERS


PRESENTATIONS


PUBLICATIONS

COMPETITORS

MARKET

  • ~20 Million

MECHANISM OF ACTION 


Opioid analgesics can act through three different types of opioid receptors, called mu, delta, and kappa. Morphine, the most widely used opioid analgesic, acts primarily via activation of the mu opioid receptor located in the central nervous system (CNS). This CNS action induces pain relief but is also associated with a wide array of CNS-mediated side effects including nausea/vomiting, sedation, respiratory depression, and abuse liability. As a way to avoid these undesirable CNS and mu opioid mediated side effects, there has been an effort to develop opioids which activate peripheral kappa opioid receptors present on sensory nerves, immune cells and the dorsal root ganglion (DRG). Such compounds, Kappa Opioid Receptor Agonists (KORAs), are thought to have the potential to provide pain relief (peripheral opioid analgesia) without producing significant CNS and mu-opioid mediated side effects.

Updated by HC

CARA, Korsuva, atopic derminititis , KARE

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

CARA DD Update...

Summary 2020 is a big year for oral Korsuva. CARA took a big hit in late 2019 from oral phase 2 data. The second phase 3 readout for IV Korsuva, KALM-II, is set to report out in Q2 ‘20. Overview Cara...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon